Gaining power and precision by using model-based weights in the analysis of late stage cancer trials with substantial treatment switching
Author:
Affiliation:
1. MRC Integrative Epidemiology Unit; University of Bristol; Bristol U.K.
2. MRC Biostatistics Unit; Cambridge U.K.
3. Pfizer; La Jolla San Diego CA U.S.A.
Funder
Medical Research Council
Publisher
Wiley
Subject
Statistics and Probability,Epidemiology
Reference18 articles.
1. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of Imatinib: a randomised controlled trial;Demetri;Lancet,2006
2. Eficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial;Motzer;Lancet,2008
3. NICE Technology appraisal 179: Sunitinib for the treatment of gastrointestinal stromal tumours 2009
4. Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred Zidovudine in symptom-free HIV infection;Concorde Coordinating Committee;Lancet,1994
5. Concorde trial of immediate versus deferred Zidovudine (letter);Gore;Lancet,1994
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Structural cumulative survival models for estimation of treatment effects accounting for treatment switching in randomized experiments;Biometrics;2022-07-10
2. A modified weighted log-rank test for confirmatory trials with a high proportion of treatment switching;PLOS ONE;2021-11-15
3. The Choice of a Randomization Procedure in Survival Studies with Nonproportional Hazards;Statistics in Biopharmaceutical Research;2021-08-17
4. A New Causal Approach to Account for Treatment Switching in Randomized Experiments under a Structural Cumulative Survival Model;2021-03-26
5. Performance of randomization-based causal methods with and without integrating external data sources for adjusting overall survival in case of extensive treatment switches in placebo-controlled randomized oncology phase 3 trials;Journal of Biopharmaceutical Statistics;2019-12-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3